Severity
Low
FDA Drug recall · Reported July 11, 2012
Defective Container; damaged blister units
Mcneil Consumer Healthcare, Div Of Mcneil-ppc, Inc. recalled Imodium Multi-Symptom Relief Caplets, Loperamide HCl 2 mg/Simethicone 125 mg, 18 count bl… - a low-severity action.
Imodium Multi-Symptom Relief Caplets, Loperamide HCl 2 mg/Simethicone 125 mg, 18 count bl… was recalled by Mcneil Consumer Healthcare, Div Of Mcneil-ppc, Inc. in July 11, 2012. Reason: Defective Container; damaged blister units. Check the official notice for the remedy. Verify recall #D-1404-2012 with the FDA Drug before acting.
The recall
Mcneil Consumer Healthcare, Div Of Mcneil-ppc, Inc. issued this low-severity FDA Drug recall-Defective Container; damaged blister units.
Sourced from official FDA Drug enforcement records. Verify recall #D-1404-2012 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1404-2012) was formally reported on July 11, 2012, with the manufacturer initiating the action on May 17, 2012. It is classified under Low severity (Class III), with a current status of Terminated. Mcneil Consumer Healthcare, Div Of Mcneil-ppc, Inc. is listed as the recalling firm, operating out of Fort Washington, PA. Federal records list the affected scope as 53,892 packages.
The documented reason for this recall is: Defective Container; damaged blister units Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
53,892 packages
Related Recalls
6
5 from same agency
Imodium Multi-Symptom Relief Caplets, Loperamide HCl 2 mg/Simethicone 125 mg, 18 count blister pack cartons, McNeil Consumer Healthcare, Div of McNeil-PPC Inc., Fort Washington, PA
Defective Container; damaged blister units
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1404-2012 |
| Date reported | July 11, 2012 |
| Date initiated | May 17, 2012 |
| Recalling firm | Mcneil Consumer Healthcare, Div Of Mcneil-ppc, Inc. |
| Firm location | Fort Washington, PA |
| Affected scope | 53,892 packages |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 11, 2012. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.